Tradestie Institutional Equity Comparison Engine

EXYN vs MDCX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MDCX Overall Edge

MDCX Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicus Pharma Ltd. Common Stock (MDCX) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, EXYN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MDCX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EXYN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MDCX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EXYN N/M vs MDCX N/M Fwd P/E
Growth & Margin Winner MDCX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner MDCX
1Y -70.0% vs -49.3% ยท 52W Pos 2% vs 23%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
EXYN US Equity
EXYN
Institutional Equity
$1.56
-9.57% 1D
Market Cap N/A
1M Return -46.02%
1Y Return -70.0%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 50.0 Mom 60.0
MDCX NASDAQ
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.14
-2.16% 1D
Market Cap $3.1M
1M Return -56.68%
1Y Return -49.33%
Forward P/E N/M
Unified AI Score
49.2 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EXYN -70.0% MDCX -49.33% Spread: +347.08 pp (MDCX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EXYN TTM Op. Margin: N/A MDCX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EXYN vs MDCX. Trailing 12-month operating profitability (EXYN N/A vs MDCX 0.0%) and valuation multiples (EXYN N/M vs MDCX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EXYN (2) vs MDCX (6)
Institutional Metric EXYN MDCX Criterion Row Winner
Market Capitalization Scale N/A $3.1M Larger Scale MDCX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth MDCX
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin MDCX
Net Profit Margin Profitability N/A 0.0% Higher Margin MDCX
Return on Equity (ROE) Capital Efficiency N/A -7446.1% Higher ROE MDCX
52-Week Range Position Momentum 2% ($1โ€“$7) 23% ($0โ€“$5) Stronger Trend MDCX
Beta / 30D Volatility Risk Regime 1.90ฮฒ ยท 85% Vol -0.28ฮฒ ยท 118% Vol Lower Realized Risk EXYN
Unified Institutional Score Composite Signal 50.1 / 100 (HOLD) 49.2 / 100 (HOLD) Higher Composite EXYN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EXYN vs MDCX Buy Guide
EXYN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EXYN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MDCX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MDCX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EXYN nor MDCX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.